Carlos Rodarte is the Founder & Managing Director of Volar Health, LLC — a strategy and innovation consultancy enabling healthcare organizations, life sciences companies, and leading startups to build and commercialize data-driven products that meaningfully improve the lives of patients.
Previously, Carlos was co-founder & CEO of HealthRhythms, a behavioral health startup discovering and developing novel digital biomarkers to improve research and enhance remote patient monitoring. By utilizing smartphone sensors, voice biomarkers, and mobility patterns, HealthRhythms was helping decode how human behaviors indicate mood anomalies.
Beforehand, at PatientsLikeMe, the leading peer-to-peer research platform, he created the companies first enterprise data subscription product and successfully commercialized it within the life sciences industry. He also led the efforts to engage patients in discovering digital biomarkers and validating digital therapeutics across patient populations.
Earlier in his career, Carlos was a life sciences strategy consultant with The Frankel Group (acquired by Huron Consulting Group), where he created R&D and commercial strategy for large pharmaceuticals to small biotech startups developing novel assets, diagnostics, and research technology platforms.
Carlos is an active startup mentor, member of several advisory boards, and internationally-recognized speaker on health innovation. In 2015, Carlos was named a “40 under 40 Healthcare Innovator” by MedTech Boston and in 2016 a “Top 100 Digital Health Influencer” by Onalytica. In 2017, he joined the Editorial Board of Digital Biomarkers, a new open-access journal by Karger Publishers. More recently, Carlos became a Venture Fellow with FundRx, a innovative Seed/Series A investment firm focused on digital medicine and life sciences.
27 – Panel: The Digitized Patient Experience: How Novel Digital Therapeutics (DTx) Data Will Reshape Your Analytics and Remote Patient Care Programs (Innovation, Life Sciences; Course Level-Intermediate)
Digital Therapeutics (DTx), defined as software-driven evidence-based therapeutic medical interventions, are used increasingly for conditions not well-addressed by mainstream medicine. These therapies collect information on a new frontier: a patient’s moment-by-moment physiological processes, emotions, behaviors, and environment. How should these highly personalized tools be implemented? How should this flood of data be governed and analyzed? How will the increased information affect the provider’s role? A panel of DTx developers will address these questions and more.